Liraglutide and DPP-4 inhibitors - side effects comparative clinical study

Liraglutide and DPP-4 inhibitors - side effects comparative clinical study

The objective of this study was to monitor the side effects of the GLP-1 receptor agonist liraglutide in comparison to those of DPP-4 inhibitors (sitagliptin and vildagliptin), in order to determine their safety, tolerability and therapeutic efficiency. The study was carried out in the "Heart a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clujul medical 2013, Vol.86 (2), p.111-113
Hauptverfasser: Timofte, Luminiţa, Stratmann, Bernd, Quester, Wulf, Bojiţă, Marius Traian, Tschoepe, Diethelm
Format: Artikel
Sprache:eng
Schlagworte:
Original Research
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 113
container_issue 2
container_start_page 111
container_title Clujul medical
container_volume 86
creator Timofte, Luminiţa
Stratmann, Bernd
Quester, Wulf
Bojiţă, Marius Traian
Tschoepe, Diethelm
description The objective of this study was to monitor the side effects of the GLP-1 receptor agonist liraglutide in comparison to those of DPP-4 inhibitors (sitagliptin and vildagliptin), in order to determine their safety, tolerability and therapeutic efficiency. The study was carried out in the "Heart and Diabetes Center NRW" and included overweight patients with type 2 diabetes whose therapeutic regimen was switched to liraglutide or DPP-4 inhibitors. A validated questionnaire method was used to monitor the side effects during the hospitalization period, then again at 3, and 6 months after the beginning of the therapy. The therapy with liraglutide was associated with more side effects than the one with DPP-4 inhibitors. In general, side effects were declining with time, thus only few patients stopped therapy. The incretin therapy turned out to be a safe and effective therapeutic option for patients with type 2 diabetes mellitus.
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4462430</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1730024471</sourcerecordid><originalsourceid>FETCH-LOGICAL-p1110-611d35c4cca9f1f7a2ce0c1f6c6addd6f769bb8e9efc1302979cfdce2b805d43</originalsourceid><addsrcrecordid>eNpVkEtLAzEUhYMottT-BcnSTSDJpMlkI0h9U7CL7kMmjzaQeZhkCv57R6yiq7v4Dt853DMwp5hzVNeCnoM5oZQiSoicgWXOocFMSCm4lJdgRvmKCknlHLxuQtL7OJZgHdSdhffbLWIwdIfQhNKnDBHMX8x570zJ0PTtoJMu4eigiaELRkeYy2g_rsCF1zG75ekuwO7xYbd-Rpu3p5f13QYNhBCMOCG2WhlmjJaeeKGpcdgQzw3X1lrup41NUzvpvCEVplJI461xtKnxyrJqAW6_tcPYtG4CXUk6qiGFVqcP1eug_pMuHNS-PyrGOGUVngQ3J0Hq30eXi2pDNi5G3bl-zIqICmPKmCBT9Ppv12_Jz_-qTylib94</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1730024471</pqid></control><display><type>article</type><title>Liraglutide and DPP-4 inhibitors - side effects comparative clinical study</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>PubMed Central</source><creator>Timofte, Luminiţa ; Stratmann, Bernd ; Quester, Wulf ; Bojiţă, Marius Traian ; Tschoepe, Diethelm</creator><creatorcontrib>Timofte, Luminiţa ; Stratmann, Bernd ; Quester, Wulf ; Bojiţă, Marius Traian ; Tschoepe, Diethelm</creatorcontrib><description>The objective of this study was to monitor the side effects of the GLP-1 receptor agonist liraglutide in comparison to those of DPP-4 inhibitors (sitagliptin and vildagliptin), in order to determine their safety, tolerability and therapeutic efficiency. The study was carried out in the "Heart and Diabetes Center NRW" and included overweight patients with type 2 diabetes whose therapeutic regimen was switched to liraglutide or DPP-4 inhibitors. A validated questionnaire method was used to monitor the side effects during the hospitalization period, then again at 3, and 6 months after the beginning of the therapy. The therapy with liraglutide was associated with more side effects than the one with DPP-4 inhibitors. In general, side effects were declining with time, thus only few patients stopped therapy. The incretin therapy turned out to be a safe and effective therapeutic option for patients with type 2 diabetes mellitus.</description><identifier>ISSN: 1222-2119</identifier><identifier>EISSN: 2066-8872</identifier><identifier>PMID: 26527929</identifier><language>eng</language><publisher>Romania: Iuliu Hatieganu University of Medicine and Pharmacy</publisher><subject>Original Research</subject><ispartof>Clujul medical, 2013, Vol.86 (2), p.111-113</ispartof><rights>2013</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4462430/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4462430/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,4010,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26527929$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Timofte, Luminiţa</creatorcontrib><creatorcontrib>Stratmann, Bernd</creatorcontrib><creatorcontrib>Quester, Wulf</creatorcontrib><creatorcontrib>Bojiţă, Marius Traian</creatorcontrib><creatorcontrib>Tschoepe, Diethelm</creatorcontrib><title>Liraglutide and DPP-4 inhibitors - side effects comparative clinical study</title><title>Clujul medical</title><addtitle>Clujul Med</addtitle><description>The objective of this study was to monitor the side effects of the GLP-1 receptor agonist liraglutide in comparison to those of DPP-4 inhibitors (sitagliptin and vildagliptin), in order to determine their safety, tolerability and therapeutic efficiency. The study was carried out in the "Heart and Diabetes Center NRW" and included overweight patients with type 2 diabetes whose therapeutic regimen was switched to liraglutide or DPP-4 inhibitors. A validated questionnaire method was used to monitor the side effects during the hospitalization period, then again at 3, and 6 months after the beginning of the therapy. The therapy with liraglutide was associated with more side effects than the one with DPP-4 inhibitors. In general, side effects were declining with time, thus only few patients stopped therapy. The incretin therapy turned out to be a safe and effective therapeutic option for patients with type 2 diabetes mellitus.</description><subject>Original Research</subject><issn>1222-2119</issn><issn>2066-8872</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNpVkEtLAzEUhYMottT-BcnSTSDJpMlkI0h9U7CL7kMmjzaQeZhkCv57R6yiq7v4Dt853DMwp5hzVNeCnoM5oZQiSoicgWXOocFMSCm4lJdgRvmKCknlHLxuQtL7OJZgHdSdhffbLWIwdIfQhNKnDBHMX8x570zJ0PTtoJMu4eigiaELRkeYy2g_rsCF1zG75ekuwO7xYbd-Rpu3p5f13QYNhBCMOCG2WhlmjJaeeKGpcdgQzw3X1lrup41NUzvpvCEVplJI461xtKnxyrJqAW6_tcPYtG4CXUk6qiGFVqcP1eug_pMuHNS-PyrGOGUVngQ3J0Hq30eXi2pDNi5G3bl-zIqICmPKmCBT9Ppv12_Jz_-qTylib94</recordid><startdate>2013</startdate><enddate>2013</enddate><creator>Timofte, Luminiţa</creator><creator>Stratmann, Bernd</creator><creator>Quester, Wulf</creator><creator>Bojiţă, Marius Traian</creator><creator>Tschoepe, Diethelm</creator><general>Iuliu Hatieganu University of Medicine and Pharmacy</general><scope>NPM</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>2013</creationdate><title>Liraglutide and DPP-4 inhibitors - side effects comparative clinical study</title><author>Timofte, Luminiţa ; Stratmann, Bernd ; Quester, Wulf ; Bojiţă, Marius Traian ; Tschoepe, Diethelm</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p1110-611d35c4cca9f1f7a2ce0c1f6c6addd6f769bb8e9efc1302979cfdce2b805d43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Original Research</topic><toplevel>online_resources</toplevel><creatorcontrib>Timofte, Luminiţa</creatorcontrib><creatorcontrib>Stratmann, Bernd</creatorcontrib><creatorcontrib>Quester, Wulf</creatorcontrib><creatorcontrib>Bojiţă, Marius Traian</creatorcontrib><creatorcontrib>Tschoepe, Diethelm</creatorcontrib><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clujul medical</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Timofte, Luminiţa</au><au>Stratmann, Bernd</au><au>Quester, Wulf</au><au>Bojiţă, Marius Traian</au><au>Tschoepe, Diethelm</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Liraglutide and DPP-4 inhibitors - side effects comparative clinical study</atitle><jtitle>Clujul medical</jtitle><addtitle>Clujul Med</addtitle><date>2013</date><risdate>2013</risdate><volume>86</volume><issue>2</issue><spage>111</spage><epage>113</epage><pages>111-113</pages><issn>1222-2119</issn><eissn>2066-8872</eissn><abstract>The objective of this study was to monitor the side effects of the GLP-1 receptor agonist liraglutide in comparison to those of DPP-4 inhibitors (sitagliptin and vildagliptin), in order to determine their safety, tolerability and therapeutic efficiency. The study was carried out in the "Heart and Diabetes Center NRW" and included overweight patients with type 2 diabetes whose therapeutic regimen was switched to liraglutide or DPP-4 inhibitors. A validated questionnaire method was used to monitor the side effects during the hospitalization period, then again at 3, and 6 months after the beginning of the therapy. The therapy with liraglutide was associated with more side effects than the one with DPP-4 inhibitors. In general, side effects were declining with time, thus only few patients stopped therapy. The incretin therapy turned out to be a safe and effective therapeutic option for patients with type 2 diabetes mellitus.</abstract><cop>Romania</cop><pub>Iuliu Hatieganu University of Medicine and Pharmacy</pub><pmid>26527929</pmid><tpages>3</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1222-2119
ispartof Clujul medical, 2013, Vol.86 (2), p.111-113
issn 1222-2119
2066-8872
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4462430
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; PubMed Central
subjects Original Research
title Liraglutide and DPP-4 inhibitors - side effects comparative clinical study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T21%3A08%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Liraglutide%20and%20DPP-4%20inhibitors%20-%20side%20effects%20comparative%20clinical%20study&rft.jtitle=Clujul%20medical&rft.au=Timofte,%20Lumini%C5%A3a&rft.date=2013&rft.volume=86&rft.issue=2&rft.spage=111&rft.epage=113&rft.pages=111-113&rft.issn=1222-2119&rft.eissn=2066-8872&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E1730024471%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1730024471&rft_id=info:pmid/26527929&rfr_iscdi=true